• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative RT-PCR using 313 Nasopharyngeal Swabs I

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2020 Aug 12;S1201-9712(20)30658-5.
doi: 10.1016/j.ijid.2020.08.029. Online ahead of print.
Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients


Yosuke Hirotsu[SUP] 1 [/SUP], Makoto Maejima[SUP] 2 [/SUP], Masahiro Shibusawa[SUP] 2 [/SUP], Yuki Nagakubo[SUP] 3 [/SUP], Kazuhiro Hosaka[SUP] 2 [/SUP], Kenji Amemiya[SUP] 4 [/SUP], Hitomi Sueki[SUP] 2 [/SUP], Miyoko Hayakawa[SUP] 5 [/SUP], Hitoshi Mochizuki[SUP] 6 [/SUP], Toshiharu Tsutsui[SUP] 7 [/SUP], Yumiko Kakizaki[SUP] 7 [/SUP], Yoshihiro Miyashita[SUP] 7 [/SUP], Shintaro Yagi[SUP] 8 [/SUP], Satoshi Kojima[SUP] 8 [/SUP], Masao Omata[SUP] 9 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is determined by reverse-transcription PCR (RT-PCR) in routine clinical practice. In the current pandemic situation, a more rapid and high-throughput method is in growing demand. Here, we validated the performance of a new antigen test (LUMIPULSE) based on the chemiluminescence enzyme immunoassay. A total of 313 nasopharyngeal swabs (82 serial samples from 7 infected patients, 231 individual samples from 4 infected patients and 215 non-infected individuals) were analyzed for SARS-CoV-2 by quantitative RT-PCR (RT-qPCR) and then subjected to LUMIPULSE. We determined the cutoff value for antigen detection using receiver operating characteristic curve analysis and compared the antigen test performance with that of RT-qPCR. Further, we compared the viral loads and antigen levels in serial samples from seven infected patients. When using RT-qPCR as the reference, the antigen test exhibited 55.2% sensitivity and 99.6% specificity with a 91.4% overall agreement rate (286/313). In specimens with > 100 viral copies and between 10 and 100 copies, the antigen test showed 100% and 85% concordance with RT-qPCR, respectively. This concordance declined with lower viral loads. In the serially followed patients, the antigen levels showed a steady decline along with viral clearance. This gradual decline was in contrast with the abrupt "positive-to-negative" and "negative-to-positive" status changes observed with RT-qPCR, particularly in the late phase of infection. In summary, the LUMIPULSE antigen test can rapidly identify SARS-CoV-2-infected individuals with moderate to high viral loads and may be helpful for monitoring viral clearance in hospitalized patients.

Keywords: COVID-19; RT-qPCR; SARS-CoV-2; antigen; immunoassay; infection.
 
Back
Top Bottom